Fig. 9: NDV treatment demonstrates tumor specificity and safety. | Gene Therapy

Fig. 9: NDV treatment demonstrates tumor specificity and safety.

From: RETRACTED ARTICLE: Optimization of oncolytic effect of Newcastle disease virus Clone30 by selecting sensitive tumor host and constructing more oncolytic viruses

Fig. 9

a Recombinant viruses rClone30-RFP and rAnh-RFP was intravenously injected into subcutaneous tumor-bearing mice or normal mice to observe the distribution of virus. Control: normal mice intravenously treated with rAnh-RFP. rClone30-RFP: tumor-bearing mice intravenously injected with rClone30-RFP. rAnh-RFP: tumor-bearing mice intravenously injected with rAnh-RFP. b The serum biochemistry data of the experimental mice after injection of recombinant viruses. After 15 injections of rClone30, rClone30-Anh(HN), rClone30-Anh(F), and rClone30-Anh(HN-F), the blood of mice was drawn for measurement of serum chemistries. Control: normal mice. Values are expressed as mean ± SEM. ALT alanine aminotransferase, AST aspartate transaminase, BUN blood urea nitrogen, CREA creatinine.

Back to article page